Answers are grounded in this paper and cite their sources.
Post-hoc analysis assesses HER2 IHC concordance and efficacy in solid tumors, suggesting a need for improved diagnostic standards.
The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.
No takes yet. Share an insight, caveat, or question.
Makker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: